Drugs / NRX 194204
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00630760 | Feb 2008 → Jun 2010 | refractory malignant neoplasm | University of Southern California | Terminated | No outcome recorded Stop: Enrollment |
| Phase 22 trials | ||||||
| Phase 2 | NCT01540071 | Aug 2011 → Dec 2015 | castration-resistant prostate carcinoma | Io Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00964132 | Mar 2009 → Mar 2010 | non-small cell lung carcinoma | NuRx Pharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NRX 194204 | “NRX 194204, a second generation rexinoid, is a highly potent and specific activator of RXRs.” NCT00964132 ↗ |
| Known as | IRX4204 | “All patients enrolled received 20 mg of IRX4204 per day orally, for six months, or longer if the patient had disease stabilization and was tolerating the experimental treatment.” NCT01540071 ↗ |
| Action | Activate | “specific activator of RXRs” NCT00964132 ↗ |
| Modality | Other / unclassified | “a second generation rexinoid” NCT00964132 ↗ |
| Route | Oral | “Oral NRX 194204” NCT00630760 ↗ |